<i>BRAF</i> Inhibitors in <i>BRAF-Mutated</i> Colorectal Cancer: A Systematic Review

<i>BRAF</i> Inhibitors in <i>BRAF-Mutated</i> Colorectal Cancer: A Systematic Review

Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths globally. <i>BRAF</i> mutation is present in about 10% of CRC patients and is associated with a poor response to chemotherapy. These patients have a relatively poor prognosis. This review aims to assess the effi...

Full description

Bibliographic Details
Main Authors:	Wajeeha Aiman, Muhammad Ashar Ali, Samer Jumean, Ummul Asfeen, Jose Garcia, Murad Quirem, Amaar Ahmad, Mohammad Nabil Rayad, Osama Alkhlaifat, Bader Al Omour, Venkata S. Chemarthi, Michael Maroules, Gunwant Guron, Hamid Shaaban
Format:	Article
Language:	English
Published:	MDPI AG 2023-12-01
Series:	Journal of Clinical Medicine
Subjects:	colorectal cancer <i>BRAF</i> mutation <i>BRAF</i> inhibitors encorafenib vemurafenib
Online Access:	https://www.mdpi.com/2077-0383/13/1/113

Similar Items

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
by: Paweł Rogala, et al.
Published: (2022-04-01)

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
by: Alexander Schulz, et al.
Published: (2022-10-01)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
by: Karisa C. Schreck, et al.
Published: (2019-08-01)

BRAF Inhibitors in Non-Small Cell Lung Cancer
by: Vincenzo Sforza, et al.
Published: (2022-10-01)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek Tanja, et al.
Published: (2016-09-01)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma
by: Omid Hamid, et al.
Published: (2019-10-01)

Tracking of Glycans Structure and Metallomics Profiles in <i>BRAF</i> Mutated Melanoma Cells Treated with Vemurafenib
by: Monika K. Nisiewicz, et al.
Published: (2021-01-01)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
by: Tiziana Notarangelo, et al.
Published: (2017-10-01)

Combination of encorafenib and binimetinib in the treatment of patients with <i>BRAF</i>-mutated advanced melanoma. Case report
by: Kristina V. Orlova, et al.
Published: (2023-05-01)

Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma Patients
by: Sarah Zhou, et al.
Published: (2021-05-01)

The Use of ctDNA for <i>BRAF</i> Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma
by: Paweł Sobczuk, et al.
Published: (2022-02-01)

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
by: Azad Saei, et al.
Published: (2018-09-01)

The Cytoprotective Role of Autophagy in Response to BRAF-Targeted Therapies
by: Ahmed M. Elshazly, et al.
Published: (2023-09-01)

The possibilities of therapy of patients with metastatic colorectal cancer with <i>BRAF</i> V600E mutation. Clinical cases
by: Elizaveta M. Polyanskaya, et al.
Published: (2023-05-01)

Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance
by: Namkyoung Kim, et al.
Published: (2021-04-01)

Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF<sup>V600E</sup> Protein
by: Elisabetta Marini, et al.
Published: (2022-12-01)

Atypical <i>BRAF</i> and <i>NRAS</i> Mutations in Mucosal Melanoma
by: Nicolas Dumaz, et al.
Published: (2019-08-01)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in <i>BRAF</i>-Mutated Metastatic Colorectal Cancer—A Case Series Study <i>Target Therapy of</i> BRAF-<i>Mutated mCRC</i>
by: Jen-Hao Yeh, et al.
Published: (2021-12-01)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
by: Fedor V. Moiseyenko, et al.
Published: (2019-05-01)

Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
by: Morgane Broudic-Guibert, et al.
Published: (2019-07-01)

Targeting <i>BRAF</i> Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
by: Frank Aboubakar Nana, et al.
Published: (2021-09-01)

Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma
by: Anne Uebel, et al.
Published: (2023-01-01)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
by: Teresa Żołek, et al.
Published: (2023-07-01)

Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
by: Gianluca Piccolo, et al.
Published: (2022-11-01)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
by: Vincenzo Di Nunno, et al.
Published: (2023-01-01)

Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma
by: Heike Niessner, et al.
Published: (2023-11-01)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
by: Carlotta Guzzetti, et al.
Published: (2023-09-01)

Imaging Mass Spectrometry for the Classification of Melanoma Based on <i>BRAF</i>/<i>NRAS</i> Mutational Status
by: Rita Casadonte, et al.
Published: (2023-03-01)

VISTA, PDL-L1, and <i>BRAF</i>—A Review of New and Old Markers in the Prognosis of Melanoma
by: Andreea Cătălina Tinca, et al.
Published: (2022-01-01)

Association of DNA Promoter Methylation and <i>BRAF</i> Mutation in Thyroid Cancer
by: Farzana Jasmine, et al.
Published: (2023-03-01)

The Transcriptional Landscape of <i>BRAF</i> Wild Type Metastatic Melanoma: A Pilot Study
by: Elena Lastraioli, et al.
Published: (2022-06-01)

A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib
by: Mary Clark, MD, et al.
Published: (2022-06-01)

<i>KRAS</i> and <i>BRAF</i> Mutation Rates and Survival Outcomes in Colorectal Cancer in an Ethnically Diverse Patient Cohort
by: Paul Habashy, et al.
Published: (2023-12-01)

<i>BRAF</i> V600E Detection in Liquid Biopsies from Pediatric Central Nervous System Tumors
by: Noemi García-Romero, et al.
Published: (2019-12-01)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
by: Stefanie Hoyer, et al.
Published: (2021-11-01)

Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?
by: Marco Crocco, et al.
Published: (2022-05-01)

<i>BRAF</i> Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies
by: Pei-Pei Wang, et al.
Published: (2022-08-01)

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01)

Developing Models to Predict <i>BRAF</i>V600E and <i>RAS</i> Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression
by: Agnes Stephanie Harahap, et al.
Published: (2023-10-01)

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
by: Meghan J. Mooradian, et al.
Published: (2018-05-01)